{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:08:15Z","timestamp":1791083295146,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.rmr.2011.07.011","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T17:16:05Z","timestamp":1332868565000},"page":"579-600","source":"Crossref","is-referenced-by-count":7,"title":["Traitement des infections tuberculeuses latentes"],"prefix":"10.1016","volume":"29","author":[{"given":"P.","family":"Fraisse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2011.07.011_bib0005","doi-asserted-by":"crossref","unstructured":"Fraisse P. Diagnostic des infections tuberculeuses latentes (sujets sains, sujets immunod\u00e9prim\u00e9s ou amen\u00e9s \u00e0 l\u2019\u00eatre). Rev Mal Resp. doi:10.1016\/j.rmr.2011.05.019, \u00e0 para\u00eetre.","DOI":"10.1016\/j.rmr.2011.05.019"},{"key":"10.1016\/j.rmr.2011.07.011_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-3156.2010.02665.x","article-title":"Viewpoint: scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection","volume":"16","author":"Zumla","year":"2011","journal-title":"Trop Med Int Health."},{"key":"10.1016\/j.rmr.2011.07.011_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/499311","article-title":"Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens","volume":"193","author":"Wilkinson","year":"2006","journal-title":"J Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0020","first-page":"682","article-title":"The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children","volume":"69","author":"Lincoln","year":"1954","journal-title":"Am Rev Tuberc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0025","first-page":"942","article-title":"Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report","volume":"76","author":"Ferebee","year":"1957","journal-title":"Am Rev Tuberc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0030","first-page":"827","article-title":"Isoniazid prophylaxis among alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0035","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0040","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Commitee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.rmr.2011.07.011_bib0045","first-page":"CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2011.07.011_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong chest service\/tuberculosis research centre, Madras\/British medical research council","volume":"145","author":"Hong Kong Chest Service","year":"1992","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0060","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0065","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection","volume":"170","author":"Reichman","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1378\/chest.76.6_Supplement.771","article-title":"Basic mechanisms of chemotherapy","volume":"76","author":"Mitchison","year":"1979","journal-title":"Chest."},{"key":"10.1016\/j.rmr.2011.07.011_bib0075","doi-asserted-by":"crossref","first-page":"3S25","DOI":"10.1016\/S0761-8425(04)71381-9","article-title":"Dans quelles circonstances et comment traiter une infection tuberculeuse latente\u00a0?","volume":"21","author":"Deschildre","year":"2004","journal-title":"Rev Mal Respir."},{"key":"10.1016\/j.rmr.2011.07.011_bib0080","first-page":"3S1","article-title":"Recommandations de la soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise pour la prise en charge de la tuberculose en france","volume":"21","author":"Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise","year":"2004","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2011.07.011_bib0085","first-page":"7S3","article-title":"Pr\u00e9vention et prise en charge de la tuberculose en france. Synth\u00e8se et recommandations du groupe de travail du CSHPF (2002\u20132003)","volume":"20","author":"Conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France","year":"2003","journal-title":"Rev Mal Resp."},{"key":"10.1016\/j.rmr.2011.07.011_bib0090","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection: experience with 157\u00a0adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0095","unstructured":"Conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France. Avis du conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de france section maladies transmissibles relatif au traitement de la tuberculose-infection (s\u00e9ance du 14\u00a0mars 2003). 2003."},{"key":"10.1016\/j.rmr.2011.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2011.07.011_bib0105","first-page":"1080","article-title":"Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis","volume":"10","author":"Gao","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0110","first-page":"535","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection \u2013 United States, 2003","volume":"52","author":"Centers for Disease Control Prevention (CDC), Society. AT","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.rmr.2011.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.7326\/0003-4819-127-12-199712150-00001","article-title":"Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35\u00a0years of age: a risk-benefit and cost-effectiveness analysis","volume":"127","author":"Salpeter","year":"1997","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0120","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1001\/archinte.1990.00390230071009","article-title":"public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors","volume":"150","author":"Colice","year":"1990","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1164\/ajrccm\/137.1.215","article-title":"Isoniazid for the tuberculin reactor: take it or leave it","volume":"137","author":"Tsevat","year":"1988","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5588\/09640569512986","article-title":"Tuberculosis transmission and the impact of intervention on the incidence of infection","volume":"6","author":"Pitman","year":"2002","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0135","first-page":"297","article-title":"A 13-year molecular epidemiological analysis of tuberculosis in San Francisco","volume":"10","author":"Cattamanchi","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0140","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0145","first-page":"161","article-title":"Long-term effects of isoniazid prophylaxis","volume":"41","author":"Ferebee","year":"1968","journal-title":"Bull Int Union Tuberc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0150","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jama.1984.03340340023018","article-title":"Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents","volume":"251","author":"Hsu","year":"1984","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2011.07.011_bib0155","first-page":"169","article-title":"Long-term isoniazid prophylaxis. Controlled trial on inh prophylaxis after recent tuberculin conversion in young adults","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Union Tuberc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/adc.78.2.169","article-title":"Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis","volume":"78","author":"Ormerod","year":"1998","journal-title":"Arch Dis Child."},{"key":"10.1016\/j.rmr.2011.07.011_bib0165","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2010.02.038","article-title":"Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection","volume":"135","author":"Salinas","year":"2010","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.rmr.2011.07.011_bib0175","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1164\/ajrccm.162.5.2003028","article-title":"Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis","volume":"162","author":"Jasmer","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0180","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00002030-199707000-00006","article-title":"Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial","volume":"11","author":"Hawken","year":"1997","journal-title":"AIDS."},{"key":"10.1016\/j.rmr.2011.07.011_bib0185","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","article-title":"Twice weekly tuberculosis preventive therapy in hiv infection in Zambia","volume":"12","author":"Mwinga","year":"1998","journal-title":"AIDS."},{"key":"10.1016\/j.rmr.2011.07.011_bib0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00042560-200111010-00018","article-title":"No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial","volume":"28","author":"Fitzgerald","year":"2001","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.rmr.2011.07.011_bib0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":"Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children","volume":"365","author":"Madhi","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMe1105555","article-title":"What is thwarting tuberculosis prevention in high-burden settings?","volume":"365","author":"Nardell","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0210","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2011.07.011_bib0215","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/bmj.39000.486400.55","article-title":"Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial","volume":"334","author":"Zar","year":"2007","journal-title":"Bmj."},{"key":"10.1016\/j.rmr.2011.07.011_bib0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in ugandan adults infected with the human immunodeficiency virus. Uganda-case western reserve university research collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0225","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/QAD.0b013e32833849df","article-title":"Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting","volume":"24","author":"van Halsema","year":"2010","journal-title":"Aids."},{"key":"10.1016\/j.rmr.2011.07.011_bib0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1157\/13048575","article-title":"Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy","volume":"21","author":"Rivero","year":"2003","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.rmr.2011.07.011_bib0235","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1164\/rccm.201004-0598OC","article-title":"Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township","volume":"182","author":"Middelkoop","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0910370","article-title":"Early versus standard antiretroviral therapy for HIV-infected adults in Haiti","volume":"363","author":"Severe","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0245","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1086\/522986","article-title":"Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries","volume":"45","author":"Brinkhof","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAD.0b013e328327964f","article-title":"Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in south africa: a prospective cohort","volume":"23","author":"Golub","year":"2009","journal-title":"AIDS."},{"key":"10.1016\/j.rmr.2011.07.011_bib0255","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"Chen","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmr.2011.07.011_bib0260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.2008.101857","article-title":"Comparison of interferon-\u03b3 release assays and conventional screening tests before tumour necrosis factor-\u03b1 blockade in patients with inflammatory arthritis","volume":"69","author":"Martin","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0265","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmr.2011.07.011_bib0270","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBnet consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0275","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","article-title":"Follow-up results of 702\u00a0patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis","volume":"30","author":"Cagatay","year":"2010","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.rmr.2011.07.011_bib0280","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0285","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmr.2011.07.011_bib0290","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0295","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/ajrccm.162.3.9804117","article-title":"Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in canadian plains Aborigines","volume":"162","author":"McNab","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0300","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMsa021099","article-title":"Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States","volume":"347","author":"Khan","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0305","first-page":"CD005435","article-title":"Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis","author":"Fraser","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.rmr.2011.07.011_bib0310","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/INF.0b013e31814523e4","article-title":"Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases","volume":"26","author":"Sneag","year":"2007","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0315","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.109.5.765","article-title":"Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up","volume":"109","author":"Schaaf","year":"2002","journal-title":"Pediatrics."},{"key":"10.1016\/j.rmr.2011.07.011_bib0320","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/INF.0b013e3181783aca","article-title":"Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York city from 1995\u00a0to 2003","volume":"27","author":"Feja","year":"2008","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0325","first-page":"61","article-title":"Management of persons exposed to multidrug-resistant tuberculosis","volume":"41","author":"Centers for Disease Control","year":"1992","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.rmr.2011.07.011_bib0330","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199404283301718","article-title":"Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis","volume":"330","author":"Horn","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0335","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ."},{"key":"10.1016\/j.rmr.2011.07.011_bib0340","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.05.00006205","article-title":"High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis","volume":"26","author":"Younossian","year":"2005","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0345","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1183\/09031936.00201609","article-title":"Tuberculosis contact investigation in low prevalence countries: an european consensus","volume":"36","author":"Erkens","year":"2010","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0350","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0355","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-associated hepatitis. Report of an outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0360","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. public health service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0365","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2011.07.011_bib0370","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7326\/0003-4819-107-6-843","article-title":"Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons","volume":"107","author":"Stead","year":"1987","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0375","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1001\/jama.1986.03380190099036","article-title":"Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks","volume":"256","author":"Comstock","year":"1986","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2011.07.011_bib0380","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1503\/cmaj.091824","article-title":"Adverse events associated with treatment of latent tuberculosis in the general population","volume":"183","author":"Smith","year":"2011","journal-title":"CMAJ."},{"key":"10.1016\/j.rmr.2011.07.011_bib0385","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest."},{"key":"10.1016\/j.rmr.2011.07.011_bib0390","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0395","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest."},{"key":"10.1016\/j.rmr.2011.07.011_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-79-1-1","article-title":"Isoniazid hepatitis","volume":"79","author":"Maddrey","year":"1973","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0405","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst","year":"2010","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0410","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199707313370505","article-title":"A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry beirn community programs for clinical research on aids","volume":"337","author":"Gordin","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-010-1571-6","article-title":"High incidence of intolerance to tuberculosis chemoprophylaxis","volume":"32","author":"Haroon","year":"2012","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.rmr.2011.07.011_bib0420","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","article-title":"High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0425","unstructured":"Y\u00e9ni P. Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH. Recommandations du groupe d\u2019experts. 2010: 418."},{"key":"10.1016\/j.rmr.2011.07.011_bib0430","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/lt.22203","article-title":"Detection and management of latent tuberculosis in liver transplant patients","volume":"17","author":"Jafri","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.rmr.2011.07.011_bib0435","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1378\/chest.123.3.967","article-title":"Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection","volume":"123","author":"Castro","year":"2003","journal-title":"Chest."},{"key":"10.1016\/j.rmr.2011.07.011_bib0440","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.811","article-title":"Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection","volume":"43","author":"Ford","year":"2011","journal-title":"Nat Genet."},{"key":"10.1016\/j.rmr.2011.07.011_bib0445","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/595689","article-title":"Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis","volume":"48","author":"Cattamanchi","year":"2009","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0450","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0455","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0460","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1164\/ajrccm.162.6.2004022","article-title":"Outcomes of contact investigations of infectious tuberculosis patients","volume":"162","author":"Marks","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0465","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York city","volume":"14","author":"Li","year":"2010","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0470","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1183\/09031936.01.00087901","article-title":"Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. Gista (gruppo italiano di studio tubercolosi e AIDS)","volume":"18","author":"Antonucci","year":"2001","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0475","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2334-10-267","article-title":"Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain","volume":"10","author":"Diaz","year":"2010","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0480","first-page":"701","article-title":"Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain","volume":"14","author":"Anibarro","year":"2010","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0485","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/pmed.2000.0654","article-title":"No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in southeast asian refugees and migrants: completion and compliance are major determinants of effectiveness","volume":"30","author":"MacIntyre","year":"2000","journal-title":"Prev Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0490","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology."},{"key":"10.1016\/j.rmr.2011.07.011_bib0495","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1183\/09031936.05.00047805","article-title":"Cost-effectiveness of isoniazid chemoprevention in close contacts","volume":"26","author":"Diel","year":"2005","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rmr.2011.07.011_bib0505","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpedi.160.3.247","article-title":"Risk of active tuberculosis among schoolchildren in Hong Kong","volume":"160","author":"Leung","year":"2006","journal-title":"Archiv Pediatr Adolesc Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0510","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0515","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4\u00a0months rifampin or 9\u00a0months isoniazid for latent TB","volume":"65","author":"Aspler","year":"2010","journal-title":"Thorax."},{"key":"10.1016\/j.rmr.2011.07.011_bib0520","unstructured":"Conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France. Enqu\u00eates autour d\u2019un cas de tuberculose. Avis du CSHPF 24-3-06 2006."},{"key":"10.1016\/j.rmr.2011.07.011_bib0525","unstructured":"Conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France. Recommandations relatives \u00e0 la lutte antituberculeuse chez les migrants en france. S\u00e9ance du 30\u00a0septembre 2005, 10p."},{"key":"10.1016\/j.rmr.2011.07.011_bib0530","unstructured":"AFSSAPS. Recommandations nationales. Pr\u00e9vention et prise en charge des tuberculoses survenant sous anti-tnf-\u03b1. Consultable sur www.afssaps.sante.fr. Juillet 2005, 6p."},{"key":"10.1016\/j.rmr.2011.07.011_bib0535","unstructured":"Haute autorit\u00e9 de sant\u00e9. Test de d\u00e9tection de la production d\u2019interf\u00e9ron gamma pour le diagnostic des infections tuberculeuses. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/rapport_detection_de_linterferon-gamma.pdf. D\u00e9cembre 2006, 50p."},{"key":"10.1016\/j.rmr.2011.07.011_bib0540","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmr.2011.07.011_bib0545","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijantimicag.2007.07.010","article-title":"Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence","volume":"30","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.rmr.2011.07.011_bib0550","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.1995.03530020061033","article-title":"Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The gruppo italiano di studio tubercolosi e AIDS (gista)","volume":"274","author":"Antonucci","year":"1995","journal-title":"JAMA."},{"key":"10.1016\/j.rmr.2011.07.011_bib0555","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0560","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7326\/0003-4819-126-2-199701150-00005","article-title":"Incidence of tuberculosis in the United States among HIV-infected persons. The pulmonary complications of HIV infection study group","volume":"126","author":"Markowitz","year":"1997","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0565","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1600-6143.2004.00545.x","article-title":"Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the united states, 1998\u20132000","volume":"4","author":"Klote","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.rmr.2011.07.011_bib0570","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rmr.2011.07.011_bib0575","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.transproceed.2006.03.029","article-title":"Mycobacterium tuberculosis infection in renal transplant recipients","volume":"38","author":"Ergun","year":"2006","journal-title":"Transplant Proc."},{"key":"10.1016\/j.rmr.2011.07.011_bib0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.TP.0000147784.53188.DC","article-title":"Tuberculosis in lung transplant recipients","volume":"79","author":"Bravo","year":"2005","journal-title":"Transplantation."},{"key":"10.1016\/j.rmr.2011.07.011_bib0585","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2004.00536.x","article-title":"Transmission of Mycobacterium tuberculosis via lung transplantation","volume":"4","author":"Winthrop","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.rmr.2011.07.011_bib0590","first-page":"341","article-title":"Tuberculosis in California dialysis patients","volume":"8","author":"Ahmed","year":"2004","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.rmr.2011.07.011_bib0595","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/thx.2010.144295","article-title":"Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease","volume":"65","author":"Milburn","year":"2010","journal-title":"Thorax."},{"key":"10.1016\/j.rmr.2011.07.011_bib0600","unstructured":"Programme national de lutte antituberculeuse. http:\/\/www.sante.gouv.fr\/htm\/dossiers\/tuberculose\/dossier_de_presse_programme-national-lutte-contre-tuberculose_20070711.pdf 2007."},{"key":"10.1016\/j.rmr.2011.07.011_bib0605","unstructured":"Haute autorit\u00e9 de sant\u00e9. Guide affection de longue dur\u00e9e. Tuberculose active. 2007: 24p."}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842512000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842512000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T04:34:32Z","timestamp":1561523672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842512000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0761842512000666"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2011.07.011","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}